GC
EGRX

Globeflex Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Globeflex Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-73,205
Closed -$3.25M – 542
2022
Q2 		$3.25M Buy
73,205
+32,000
+78% +$1.47M 0.79% 19
2022
Q1 		$2.04M Hold
41,205
– – 0.41% 56
2021
Q4 		$2.1M Hold
41,205
– – 0.43% 52
2021
Q3 		$2.3M Sell
41,205
-1,152
-3% -$56.7K 0.5% 42
2021
Q2 		$1.81M Buy
42,357
+8,094
+24% +$334K 0.33% 91
2021
Q1 		$1.43M Hold
34,263
– – 0.26% 124
2020
Q4 		$1.6M Buy
34,263
+713
+2% +$33.3K 0.34% 81
2020
Q3 		$1.43M Buy
33,550
+1,848
+6% +$80.8K 0.38% 70
2020
Q2 		$1.52M Buy
31,702
+12,951
+69% +$646K 0.39% 61
2020
Q1 		$863K Hold
18,751
– – 0.27% 129
2019
Q4 		$1.13M Buy
18,751
+9,873
+111% +$589K 0.21% 159
2019
Q3 		$502K Hold
8,878
– – 0.11% 289
2019
Q2 		$494K Hold
8,878
– – 0.1% 290
2019
Q1 		$448K Buy
8,878
+1,378
+18% +$61.3K 0.09% 309
2018
Q4 		$302K Hold
7,500
– – 0.07% 342
2018
Q3 		$520K Sell
7,500
-3,700
-33% -$281K 0.1% 292
2018
Q2 		$847K Sell
11,200
-19,700
-64% -$1.24M 0.17% 203
2018
Q1 		$1.63M Buy
30,900
+4,682
+18% +$272K 0.34% 86
2017
Q4 		$1.4M Buy
+26,218
New +$1.46M 0.39% 65
2017
Q1 		– Sell
-12,700
Closed -$1.01M – 557
2016
Q4 		$1.01M Buy
+12,700
New +$923K 0.25% 152
2016
Q3 		– Sell
-8
Closed – – 556
2016
Q2 		$0 Hold
8
– – ﹤0.01% 531
2016
Q1 		$0 Sell
8
-4,905
-100% -$311K ﹤0.01% 501
2015
Q4 		$436K Buy
4,913
+9
+0.2% +$711 0.12% 245
2015
Q3 		$363K Buy
4,904
+4,900
+122,500% +$408K 0.08% 314
2015
Q2 		$0 Buy
+4
New +$261 ﹤0.01% 596

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Globeflex Capital's EGRX Position: Q3 2022 in Review

Globeflex Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 73,205 shares — an estimated $3.25M sold.

Globeflex Capital first reported a position in EGRX in Q2 2015 and held it in 25 quarters. The position peaked at $3.25M in Q2 2022. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

  • Globeflex Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Globeflex Capital sold 73,205 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $3.25M.
  • Globeflex Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 25 quarters.
  • Globeflex Capital's Eagle Pharmaceuticals, Inc. position peaked at $3.25M in Q2 2022.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Globeflex Capital's 13F filing for Q3 2022, filed 14 Nov 2022.